APA (7th ed.) Citation

S, G., L, M., ND, J., A, S., O, E., H, A., . . . NW, C. (2025). Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: A randomised phase 3 trial of the STAMPEDE platform protocol. The Lancet. Oncology, 26(8), 1018. https://doi.org/10.1016/S1470-2045(25)00231-1

Chicago Style (17th ed.) Citation

S, Gillessen, et al. "Metformin for Patients with Metastatic Prostate Cancer Starting Androgen Deprivation Therapy: A Randomised Phase 3 Trial of the STAMPEDE Platform Protocol." The Lancet. Oncology 26, no. 8 (2025): 1018. https://doi.org/10.1016/S1470-2045(25)00231-1.

MLA (9th ed.) Citation

S, Gillessen, et al. "Metformin for Patients with Metastatic Prostate Cancer Starting Androgen Deprivation Therapy: A Randomised Phase 3 Trial of the STAMPEDE Platform Protocol." The Lancet. Oncology, vol. 26, no. 8, 2025, p. 1018, https://doi.org/10.1016/S1470-2045(25)00231-1.